In addition to the enhanced capacity of NCCN-IPI for predicting prognosis in DLBCL, the results of our study revealed that PB-CD11b+CX3CR1+ monocyte level might be used to further discriminate the risk of disease progression and death in higher risk NCCN-IPI subgroup. This evidence concerns the gene ITGAM and diffuse large B-cell lymphoma.